Janssen Pharmaceutica Nv

Yin Liang

Keith T Demarest

Gee-Hong Kuo

Guozhang Xu

John M Ryan

Micheal D Gaul

James M Lenhard

Gregory C Leo

Tonya L Martin

Abraham B Woldu

Lisa Wu

Lisa E Wu

The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.

Combination therapy for the treatment of diabetes

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators

Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows: wherein ring W, R, R, R, R, R, A, and Z, are defined herein.

GPR40 agonists in anti-diabetic drug combinations

Presented here are methods using alpha-methylglucoside (AMG) in vivo as an indicator for glucose absorption from the gastrointestinal (GI) system or glucose excretion in the urine after oral administration of AMG. The methods find use in, for example, but not limited to, determining the effect of a sodium-dependent glucose transporter (SGLT) inhibitor in an animal, comparing the differences in the effects of a first and second SGLT inhibitor in an animal, and diagnosing a disease associated with glucose absorption from the gastrointestinal (GI) system or glucose excretion from the kidney in an animal.

Methods of using alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion

Growing community of inventors

Ambler, PA, United States of America

Yin Liang